Bryophyllum vs. Nifedipine
Information source: Weleda AG
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Tocolysis
Intervention: Bryophyllum p. (Drug)
Phase: Phase 2/Phase 3
Status: Not yet recruiting
Sponsored by: Weleda AG Official(s) and/or principal investigator(s):
Roland Zimmermann, Prof. Dr. med., Principal Investigator, Affiliation: Department of Obstetrics, University Zuerich
Summary
In a prospective, randomised study the efficacy and tolerability of bryophyllum p. (p. o) vs.
nifedipine (p. o) will be proofed in a defined group of pregnant women with threatened
preterm labour.
Clinical Details
Official title: Bryophyllum p. Versus Nifedipine for the Treatment of Premature Contractions
Study design: Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Female
Exclusion Criteria:
- Bishop Score > 5
Locations and Contacts
Department of Obstetrics, University of Zuerich, Zuerich 8091, Switzerland
Additional Information
Bryophyllum p. vs nifedipine in preterm labour
Related publications: Plangger N, Rist L, Zimmermann R, Mandach UV. Intravenous tocolysis with Bryophyllum pinnatum is better tolerated than beta-agonist application. Eur J Obstet Gynecol Reprod Biol. 2005 Jul 25; [Epub ahead of print] Gwehenberger B, Rist L, Huch R, von Mandach U. Effect of Bryophyllum pinnatum versus fenoterol on uterine contractility. Eur J Obstet Gynecol Reprod Biol. 2004 Apr 15;113(2):164-71. Vilaghy I. [Decreasing the rate of premature delivery with phytotherapy--results from general practice] Ther Umsch. 2002 Dec;59(12):696-701. German.
Starting date: November 2006
Ending date: October 2008
Last updated: October 19, 2006
|
